Jeffrey A Engelman

Jeffrey A Engelman

UNVERIFIED PROFILE

Are you Jeffrey A Engelman?   Register this Author

Register author
Jeffrey A Engelman

Jeffrey A Engelman

Publications by authors named "Jeffrey A Engelman"

Are you Jeffrey A Engelman?   Register this Author

100Publications

6028Reads

49Profile Views

Distinct evolutionary paths to TKI resistance in NSCLC.

Cell Cycle 2018 29;17(3):298-299. Epub 2018 Jan 29.

a Massachusetts General Hospital Cancer Center , Charlestown , MA , USA.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/15384101.2016.1
Publisher Site
http://dx.doi.org/10.1080/15384101.2016.1221024DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5914907PMC
September 2019

Hyperactivation of MAPK Signaling Is Deleterious to RAS/RAF-mutant Melanoma.

Mol Cancer Res 2019 01 10;17(1):199-211. Epub 2018 Sep 10.

Oncology, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1541-7786.MCR-18-0327DOI Listing
January 2019

Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases.

J Thorac Oncol 2017 03 2;12(3):458-466. Epub 2016 Nov 2.

Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts; Department of Pathology, Harvard Medical School, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.10.015DOI Listing
March 2017

Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small Cell Lung Cancer.

J Thorac Oncol 2016 11 17;11(11):2027-2032. Epub 2016 Aug 17.

Massachusetts General Hospital Cancer Center, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.08.126DOI Listing
November 2016

Acquired Resistance to First-Line Afatinib and the Challenges of Prearranged Progression Biopsies.

J Thorac Oncol 2016 11 20;11(11):2022-2026. Epub 2016 Aug 20.

Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864163084
Publisher Site
http://dx.doi.org/10.1016/j.jtho.2016.06.032DOI Listing
November 2016

Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment.

J Thorac Oncol 2016 11 24;11(11):1869-1878. Epub 2016 Aug 24.

Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts; Department of Pathology, Harvard Medical School, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.08.134DOI Listing
November 2016

Plasma T790M Result Alters Treatment Options in a Previously T790 Wild-Type EGFR-Mutant Lung Cancer.

J Thorac Oncol 2016 08 12;11(8):e95-e97. Epub 2016 Apr 12.

Massachusetts General Hospital Cancer Center, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.03.020DOI Listing
August 2016

Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.

J Thorac Oncol 2016 08 22;11(8):1242-1245. Epub 2016 Jun 22.

Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.06.013DOI Listing
August 2016

Crizotinib Resensitization by Compound Mutation.

N Engl J Med 2016 05;374(18):1790-1

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1601366DOI Listing
May 2016

Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib.

JAMA Oncol 2016 Apr;2(4):541-3

Massachusetts General Hospital Cancer Center, Boston2Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2015.5009DOI Listing
April 2016

Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment.

J Natl Cancer Inst 2016 Feb 7;108(2). Epub 2015 Nov 7.

: Edwin L. Steele Laboratories, Department of Radiation Oncology (VA, GBF, DPK, MB, RCS, GS, JK, TV, JDM, KN, DB, XQ, DGD, PH, DF, RKJ), Department of Pathology (MKS, EB), and Department of Medicine, Cancer Center (JAE), Massachusetts General Hospital and Harvard Medical School, Boston MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djv313DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4862418PMC
February 2016

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.

N Engl J Med 2016 Jan 23;374(1):54-61. Epub 2015 Dec 23.

Massachusetts General Hospital Cancer Center (A.T.S., L.F., J.F.G., L.D., R.L.F., K.R.S., J.L., G.G., J.A.E.) and the Department of Pathology (A.J.I., L.L., G.G.), Massachusetts General Hospital, Boston, and the Broad Institute of the Massachusetts Institute of Technology and Harvard, Cambridge (I.L., G.G.) - all in Massachusetts; Pfizer Worldwide Research and Development, La Jolla, CA (S.B., A.B., B.J.B., Y.-L.D., W.L., L.P.J., T.S., S.T., M.M., T.W.J.); and the Japanese Foundation for Cancer Research, Tokyo (R.K.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1508887DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4773904PMC
January 2016

The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.

Clin Cancer Res 2015 Sep 11;21(17):3924-33. Epub 2015 May 11.

Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Boston, Massachusetts. Department of Medicine, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-0560DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4587765PMC
September 2015

[(18)F]-FLT PET to predict early response to neoadjuvant therapy in KRAS wild-type rectal cancer: a pilot study.

Ann Nucl Med 2015 Jul 22;29(6):535-42. Epub 2015 Apr 22.

Vanderbilt University Institute of Imaging Science (VUIIS), Vanderbilt University Medical School, 1161 21st Ave. S., AA1105 MCN, Nashville, TN, 37232-2310, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12149-015-0974-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503488PMC
July 2015

Inconsistency and features of single nucleotide variants detected in whole exome sequencing versus transcriptome sequencing: A case study in lung cancer.

Methods 2015 Jul 23;83:118-27. Epub 2015 Apr 23.

Department of Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, TN 37203, United States; Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, TN 37232, United States; Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, TN 37232, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ymeth.2015.04.016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4509831PMC
July 2015

Reply to Ciccolini et al.: Using mathematical modeling to predict response to antiangiogenic therapy in cancer patients.

Proc Natl Acad Sci U S A 2015 Jul 16;112(27):E3454. Epub 2015 Jun 16.

Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1507225112DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4500270PMC
July 2015

Transformation from NSCLC to SCLC: when did it happen? - Authors' reply.

Lancet Oncol 2015 Jul;16(7):e309-10

Massachusetts General Hospital Cancer Center, Department of Medicine and Harvard Medical School, Boston, MA 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(15)00058-3DOI Listing
July 2015

The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics.

Cancer Discov 2015 May 20;5(5):475-87. Epub 2015 Apr 20.

Virginia Commonwealth University Philips Institute for Oral Health Research, School of Dentistry and Massey Cancer Center, Richmond, Virginia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-15-0011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727530PMC
May 2015

Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin.

Lancet Oncol 2015 Apr;16(4):e165-72

Massachusetts General Hospital Cancer Center, Department of Medicine and Harvard Medical School, Boston, MA 02114, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(14)71180-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470698PMC
April 2015

Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.

Clin Cancer Res 2015 Jan 28;21(1):166-74. Epub 2014 Oct 28.

Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan. Department of Medical Genome Science, Graduate School of Frontier Science, The University of Tokyo, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/content/early/2014/12/
Web Search
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-14-1385DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4286456PMC
January 2015

Anchored multiplex PCR for targeted next-generation sequencing.

Nat Med 2014 Dec 10;20(12):1479-84. Epub 2014 Nov 10.

1] Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA. [2] Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm.3729DOI Listing
December 2014

Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.

Clin Cancer Res 2014 Nov 16;20(22):5686-96. Epub 2014 Sep 16.

Massachusetts General Hospital Cancer Center, Charlestown, Massachusetts. Department of Medicine, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-1511DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4233168PMC
November 2014

The double life of p85.

Cancer Cell 2014 Oct;26(4):445-7

Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2014.09.011DOI Listing
October 2014

Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers.

Cancer Res 2014 Jun 27;74(11):3146-56. Epub 2014 Mar 27.

Authors' Affiliations: Massachusetts General Hospital Cancer Center, Charlestown; Department of Medicine, Harvard Medical School; Department of Medical Oncology, Dana-Farber Cancer Institute; and Department of Pathology, Massachusetts General Hospital, Boston, MassachusettsAuthors' Affiliations: Massachusetts General Hospital Cancer Center, Charlestown; Department of Medicine, Harvard Medical School; Department of Medical Oncology, Dana-Farber Cancer Institute; and Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-13-3728DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4046322PMC
June 2014

Ceritinib in ALK-rearranged non-small-cell lung cancer.

N Engl J Med 2014 06;370(26):2537-9

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1404894DOI Listing
June 2014

Not just gRASping at flaws: finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers.

Cancer Sci 2014 May 26;105(5):499-505. Epub 2014 Mar 26.

Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Ishikawa, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cas.12383DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317830PMC
May 2014

Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit.

Cancer Discov 2014 Apr 20;4(4):452-65. Epub 2014 Jan 20.

Departments of 1Medical Oncology and 2Cancer Biology, Dana-Farber Cancer Institute; 3Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston; 4Broad Institute of Harvard and MIT, Cambridge; 5MGH Cancer Center, 6Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Charlestown, Massachusetts; and 7Department of Surgery, Division of Biology and Biomedical Sciences, Washington University, St. Louis, Missouri.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0646DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3980023PMC
April 2014

Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors.

J Thorac Oncol 2014 Mar;9(3):316-23

*Lowe Center for Thoracic Oncology and the Belfer Institute for Applied Cancer Science, Dana Farber Cancer Institute, Boston, Massachusetts; †Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; ‡Translational Medicine, Exelixis, Inc., South San Francisco, San Francisco, California; §Translational and Experimental Medicine, Sanofi, Vitry-sur-Seine, France; ‖Center for Thoracic Centers, Massachusetts General Hospital Cancer Center, Charlestown, Massachusetts; ¶Clinical Development Oncology, Sanofi, Cambridge, Massachusetts; #Pharmacokinetic Modeling and Simulation, Sanofi, Cambridge, Massachusetts; **Biostatistics and Programming, Sanofi, Cambridge, Massachusetts; ††Early Drug Development Center, Dana-Farber Cancer Institute, Boston, Massachusetts; ‡‡Department of Medical Oncology, Vall d'ebron University Hospital, Barcelona, Spain.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864153021
Publisher Site
http://dx.doi.org/10.1097/JTO.0000000000000088DOI Listing
March 2014

ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.

Cancer Cell 2014 Mar;25(3):282-303

Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccr.2014.02.025DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4018830PMC
March 2014

Ceritinib in ALK-rearranged non-small-cell lung cancer.

N Engl J Med 2014 Mar;370(13):1189-97

From Massachusetts General Hospital, Boston (A.T.S., J.A.E.); Seoul National University Hospital, Seoul, South Korea (D.-W.K.); Fox Chase Cancer Center, Philadelphia (R.M.); National Cancer Center and Genome Institute of Singapore, Singapore (D.S.W.T.); Vall d'Hebron University, Barcelona (E.F.); University of Washington, Seattle (L.Q.M.C.); University of Colorado, Denver (D.R.C.); University Hospital KU Leuven, Leuven, Belgium (J.V.); Huntsman Cancer Institute, Salt Lake City (S.S.); Istituto Europeo di Oncologia (T.D.P.) and Istituto di Ricovero e Cura a Carattere Scientifico Istituto Clinico Humanitas (A.S.) - both in Milan; Memorial Sloan-Kettering Cancer Center, New York (G.J.R.); Peter MacCallum Cancer Center, Melbourne, VIC, Australia (B.J.S.); Center for Integrated Oncology, University Hospital Cologne, Cologne (J.W.), Thoraxklinik, University of Heidelberg, Translational Lung Research Center Heidelberg, German Center for Lung Research (M.T.), and German Cancer Consortium (M.S.), Heidelberg, and University Duisburg-Essen, Essen (M.S.) - all in Germany; Princess Margaret Cancer Center, Toronto (G.L.); and Novartis Institutes for BioMedical Research, Cambridge, MA (Y.Y.L., M.G., A.L.B.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1311107DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4079055PMC
March 2014

mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1.

Cancer Discov 2014 Jan 25;4(1):42-52. Epub 2013 Oct 25.

1Massachusetts General Hospital Cancer Center; 2Department of Medicine, Harvard Medical School; 3Division of Gastroenterology, Department of Medicine, Tufts Medical Center; 4Department of Pathology, Massachusetts General Hospital, Boston; and 5Radiation Oncology, Steele Lab for Tumor Biology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0315DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3973435PMC
January 2014

Tyrosine kinase gene rearrangements in epithelial malignancies.

Nat Rev Cancer 2013 Nov 17;13(11):772-87. Epub 2013 Oct 17.

Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrc3612DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3902129PMC
November 2013

Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.

Clin Cancer Res 2013 Oct 15;19(19):5390-401. Epub 2013 Aug 15.

Authors' Affiliations: Departments of Medicine and Cancer Biology, Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center; Vanderbilt University, Nashville, Tennessee; Massachusetts General Hospital Cancer Center; and Department of Medicine, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-1038DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3809918PMC
October 2013

Acquired resistance to crizotinib from a mutation in CD74-ROS1.

N Engl J Med 2013 09;369(12):1173

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1309091DOI Listing
September 2013

Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer.

Sci Signal 2013 Sep 24;6(294):re6. Epub 2013 Sep 24.

1Massachusetts General Hospital Cancer Center, Charlestown, MA 02129, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scisignal.2004652DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3876281PMC
September 2013

ALK in lung cancer: past, present, and future.

J Clin Oncol 2013 Mar 11;31(8):1105-11. Epub 2013 Feb 11.

Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.44.5353DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4209068PMC
March 2013

Apoptosis in targeted therapy responses: the role of BIM.

Adv Pharmacol 2012 ;65:519-42

Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02129, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/B978-0-12-397927-8.00016-6DOI Listing
February 2013

Genetic changes in squamous cell lung cancer: a review.

J Thorac Oncol 2012 May;7(5):924-33

Department of Hematology Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e31824cc334DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3404741PMC
May 2012